Barclays raised the firm’s price target on Regeneron to $1,020 from $935 and keeps an Overweight rating on the shares. The analyst remains positively biased on U.S. biopharmaceuticals into most Q4 setups, “leaning into recent winners.” The firm recommends weighting towards names with strong prescription trends, supportive guides and potential upside to 2024 numbers. It prefers Eli Lilly (LLY), Merck (MRK), AbbVie (ABBV) Regeneron (REGN). Barclays says Bristol-Myers (BMY) and Pfizer (PFE) are the “most challenged.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron price target raised to $1,104 from $941 at Morgan Stanley
- Regeneron price target raised to $956 from $895 at Piper Sandler
- Regeneron, Sanofi announce U.S. FDA updated the label for Dupixent
- Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
- Twilio upgraded, Nutrien downgraded: Wall Street’s top analyst calls